Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in ...

Moderna's updated Spikevax shows strong antibody response and safety, targeting dominant COVID-19 variants like LP.8.1 in ...

Moderna said the 2025-2026 formula of its Covid-19 vaccine produced a strong immune response against the dominant LP.8.1 variant. The company said a preliminary analysis from a phase four clinical ...

If you're not over 65 or have certain risk factors, it might be hard to get one but not necessarily impossible. Here's what ...

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) announced clinical trial data to reaffirm the effectiveness and safety of their messenger RNA-based COVID shots on Tuesday after President Donald Trump ...

Moderna has settled related lawsuits that accused it of misusing Alnylam Pharmaceuticals' patented technology in its COVID-19 ...

Speaking at a WIRED event Tuesday, Moderna CEO Stéphane Bancel said he was “encouraged” by the company’s dialogue with the ...

Moderna says the first trial volunteers have received boosters of their vaccine, some of them modified to target a variant. Moderna announced Wednesday that the first trial volunteers have received ...

While mRNA changed the game in vaccines, leveraging the technology to develop treatments has been trickier to navigate.

The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters from Pfizer, Moderna ...

The “newly approved sources of authority” include the American College of Obstetricians and Gynecologists (ACOG), the ...

Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary ...